Skip to main content
  • Cyclosporine A Flops for PCI Cardioprotection

    The addition of cyclosporine A to percutaneous coronary intervention (PCI) did not confer protective effects against reperfusion injury, which may occur during the process of myocardial salvage, the CYCLE trial showed.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details